ARTICLE | Clinical News
Spiriva Respimat regulatory update
February 17, 2017 4:45 PM UTC
FDA approved Spiriva Respimat tiotropium bromide from Boehringer for long-term maintenance treatment of asthma in patients ages 6-11. The drug is marketed for the indication in patients ages ≥12. Spir...
BCIQ Company Profiles
BCIQ Target Profiles